# Medicare Starts Paying for Obesity Drugs as Local Health Plans Buckle - Healthcare Policy: Drug Pricing, IRA & Managed Care - Week of June 29 to July 4, 2026

> CMS switched on the Medicare GLP-1 Bridge Program on July 1, the government's first coverage of obesity drugs for seniors at a negotiated $245, even as Massachusetts towns dropped weight-loss coverage to save jobs and IQVIA data showed GLP-1s are just one point of 2025's 10.6% drug-spend growth. Our synthesis of the healthcare policy podcast tape for the week of June 29 to July 4, 2026.

## Healthcare Policy: Drug Pricing, IRA & Managed Care

### Week of June 29 to July 4, 2026: Medicare Starts Paying for Obesity Drugs as Local Health Plans Buckle

---

## Intro

The IRA negotiation machinery went quiet this week, no fresh chatter on the 2028 selected-drug list, the pill penalty, or MFN. What filled the vacuum is the story that actually moves P&Ls right now: GLP-1s colliding with public and municipal balance sheets. On July 1, CMS switched on the **Medicare GLP-1 Bridge Program**, the government's first crack at covering obesity drugs for seniors, and it did so the same week that Massachusetts towns were voting to *drop* weight-loss coverage to save teacher jobs. That split screen is the whole debate. Below, what the operators and the data people are saying, versus the pundits.

## TL;DR

- **Medicare started paying for obesity drugs this week**, but through a jury-rigged program that runs *outside* Part D, sunsets end-2027, and that private plan sponsors already refused to touch voluntarily.
- **The GLP-1 cost panic is real at the plan level but overstated at the system level:** GLP-1s are only ~1 point of 2025's 10.6% U.S. drug-spend growth, per IQVIA, the rest is broad, sticky innovation.
- **The read-through risk is migrating** from pharma pricing to *coverage*: 340B rebates, ACA subsidy cliffs, and Medicaid work-reporting are the live wires for hospitals and exchange insurers.

## What's new

**1. Medicare's obesity coverage arrived, as a workaround, not a policy.** On [NEJM Interviews](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOjk9XmTMNu2o7EDblubrzURPcMUUbdvR5Kk4Svq9Ee0o9CoBl-2BZi-2BVb1Eu-2B2ciZtetIDUoHwnMAWjJbVAfDshHQ-2BNX8j0Vdis25NssN2cD2hQ-3D-3DDXxt_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXCFer42JBFsKuMJ5Dk1W6V6GuH6R548-2FNCtHhtbAl0f4134XZqUCUD16tDgcNL9-2F-2BETO-2FcP9E2pzQ9VnnSCCcnJOWHuLUn00bSLMvdC3GGx5Q2ROhOMiJaSHU7A-2FOqcBSMQVnNWxghqO1BGJTMJt00cEYVmv7ygyvTnjifHQK-2FGA-3D-3D) (Jun 24), Vanderbilt health-policy professor **Stacie Dusetzina** (insider/academic) explained that Part D has banned weight-loss coverage since 2003, a relic of the Fen-Phen era. The new Bridge Program "is running completely outside of the Medicare Part D benefit... the government is paying for these drugs separate from the program." Crucially, the more ambitious **Balance** demonstration was shelved because "Part D plan sponsors... were not interested in participating in this voluntary model." Bridge runs July 1, 2026 through end-2027, uses a clunky deny-then-resubmit claims flow, and, per Dusetzina, awareness is "quite low," pointing to "a really slow start." *Why it matters: the plans voting with their feet against voluntary obesity risk tells you exactly how they're modeling the utilization trend.*

**2. There's a negotiated price, and it's $245.** On [Off the Chart](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgpQX94rySoulhMBrTD-2FJBbraJqlSacCQ4d5pdAq6QLQootQM7iCPkSrRHn70E4se27UMw2K0rpwC6SGDpbS46m3Mp5tIC4MZG0nW7zfqEteg-3D-3DT3nF_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXCFer42JBFsKuMJ5Dk1W6V6GuH6R548-2FNCtHhtbAl0fyi7umh3s7sM5aZEFdJr-2FjmhZNAX1yjZh2Wfybi3w9GilTAodOLzl6qDGOgPpTOQJpMk-2Bob2Kr6wcDldIxAX79zuPLqB85I8ojxQpYEqmnoNjXV1XFMQIq9K3RtGlwEhxQ-3D-3D) (Jun 29), the Obesity Action Coalition's **Tracy Zvenyach** (insider/advocacy) confirmed the administration negotiated GLP-1s to **$245**, below both retail list and current cash-pay programs, and that the program has now been *split*: Medicare gets Bridge, while Balance survives only for state Medicaid (voluntary, applications open through July 31). Eligibility is BMI-tiered at 27/30/35. *Why it matters: $245 is a low-price, high-volume construct, good for units, thin on margin, and a new anchor point for every payer negotiation that follows.*

**3. Municipal and employer plans are already breaking.** [The Journal](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOhF92CTns4OevzxPoAUZMswrSkNSj4DwgFZpOliF0WEO6lFkYRxnGFSAfP03Jx-2FUEpCgBsRCw5pA4a1aPg8-2FOuYbXJY-2FgzcY-2FqQ9-2BRjPu-2F31Q-3D-3DVnqO_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXCFer42JBFsKuMJ5Dk1W6V6GuH6R548-2FNCtHhtbAl0f5CJcs4BkaSqP4m-2BiEvVX1RdHul7KlSo7XRM3iaZoZyFRKJy2VlilRs7B8EpoTj4wmKeLxn9E0RsXy0HEwPXw2PJ9QvPJYZvmOAj9oIy6NaTLLdXGmYhgnYvJmpnFmiUVw-3D-3D) (Jun 29, WSJ, pundit/reporting) documented a Massachusetts regional insurance trust pushed "on the verge of insolvency," issuing a mid-year surprise assessment. In one town, Duxbury, "7% of its members account for 25% of total pharmacy claims related to GLP-1s prescribed for weight loss alone." Belchertown's trust ultimately *eliminated* GLP-1 weight-loss coverage (keeping it for diabetes). One town manager is asking employees to choose between a raise and the same health benefits. *Why it matters: this is the commercial/self-insured cost curve in miniature, months ahead of the 2027 renewal cycle.*

**4. The contrarian data point, GLP-1s aren't the whole story.** On [The Astonishing Healthcare Podcast](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOhsMYcaFtWA6fhUjih0IcwGKx40ep334UPLiHJapb9hxc3Rgwsbis21bTr1bxWlWOEBjSh9DXN-2FtOiGFrc-2F-2BazZet58FCO4zgt0x-2BBa50POlQ-3D-3DV6EP_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXCFer42JBFsKuMJ5Dk1W6V6GuH6R548-2FNCtHhtbAl0f5jmkI6K6AFcqCJ3lAqdJs87gz-2BcFpHq41mcfBIXg-2FsVv276GXTOPYWmtZSPhh34UDehXsHZ93XB3FVgDeAA7J2m9ohccx61etVOc-2BPIuYZJDX7c5xVGrfOt356N2J8tgA-3D-3D) (Jun 26), **IQVIA's Michael Kleinrock** (insider/data) put 2025 U.S. drug spend at **$606B, up 10.6%**, and noted that stripping out GLP-1s and COVID, growth was still **9.6%**. "It's only a percentage point of the current growth." The real engine: 28 drugs each grew >$500M, contributing $29.5B of $58B total growth ex-GLP-1, across oncology, immunology, and neurology. He also flagged ~29% of new prescriptions go unfilled, and nearly a million Medicare patients sit above the out-of-pocket cap paying cash. *Why it matters: the GLP-1 headline is starving the broader innovation-driven spend story of oxygen, and that broader story is what keeps drug budgets compounding at mid-single-digits through 2030.*

## The debate: should public payers cover GLP-1s for weight loss?

**Cover it (steel-man).** You're treating the root cause. As one Massachusetts state-plan advocate put it on The Journal, cutting GLP-1s means "we're cutting off treatment while we keep paying for everything else, the cardiac drugs, the blood pressure medications, the ER visits, hospitalizations." Obesity is a chronic disease; Bridge/Balance finally build a coverage pathway; and a $245 negotiated price makes the math defensible.

**Don't (steel-man).** The costs are immediate and enormous; the offsets are speculative and decades out. On [Actuary Voices](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgq4-2BX7uJGZCb7Vdw7UnNvTScGvnn93RPg8JmXSkntQduEM9ioZLpKWGLfEzKEjLIp-2FmPp7ffALQ7UeG9MaoyOKCQHfbQM3nQkHEi8HUkX3Xw-3D-3D0Pru_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXCFer42JBFsKuMJ5Dk1W6V6GuH6R548-2FNCtHhtbAl0fwG45-2FFsISRjCBCFFaFxHL8zGuoR8H1c2OmPmnpBfnMB-2FLuK-2B6v0AxFmtJpmfRs7D6PpbNR8yNGRhAOGmQVfSCVAs4ThfUkxRL4U77udt5vTkdpBouOQAgC1QI-2F18aAGhQ-3D-3D) (Jun 25), actuary **Kimberly Ferrero** (insider) noted "some large pharmacy coalitions are reporting that a handful of GLP-1 receptor agonists account for over 20% of total prescription spending," a class scaling faster than actuaries have ever priced, while long-term adherence and durability data remain "very immature." Add gaming risk (patients "exaggerate something," per The Journal) and hard budget crowd-out, and caution is rational. Kleinrock's framing sits underneath both sides: at the *system* level, GLP-1s are a rounding error on growth, and the panic may be misallocating policy attention.

## Read-throughs

- **GLP-1 makers (LLY, NVO):** Bridge adds incremental Medicare volume, but at $245 and with a 2027 sunset and slow ramp, it's units over margin. On [Everybody's Business](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOixiQxDWxveV5sP71yEjdV9l21RrA7JyTo8xzsBLjD-2B-2FS-2FzuTuWx1mwyPKHVq-2BvqYtfq1baeXceVFkuPdHwIDe5KbBm0vSRgyZTzIHOegGtWA-3D-3DLrV5_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXCFer42JBFsKuMJ5Dk1W6V6GuH6R548-2FNCtHhtbAl0f4MQXzlgWZCty-2FHdGJJ8ezDuy9syYrt22lZj-2BaqAzJHNZwdWuVenBNm1elzZ46AY-2FJ8wj1mUQdVvQjrDMbfio3TRph1kauj6lWxjsVO-2BfKnuDL8uNHv6YMT4nv4-2BpKG6WA-3D-3D) (Jun 26, Bloomberg, pundit), reporters noted Lilly (now ~$1T cap) and Novo struck the deal to expand Medicare obesity access, and that Trump said Lilly "wouldn't be subject to tariffs because they were building in the U.S.," a relative competitive positive worth watching if pharma tariffs land.
- **Part D sponsors / managed care (UNH, CVS, HUM, ELV):** Their refusal to join Balance voluntarily keeps obesity utilization *off* their MLR for now, but signals how they view the trend. Bridge sitting outside Part D is a temporary shield, not a solution.
- **Medicaid & exchange insurers (CNC, MOH, ELV):** The live risk. On [Paging America](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOj-2B4GTaPi-2FhHt-2BYJPFB-2B8PtNPrO5hAFexYIIaRikVnYmAhi-2FwWSCNtckH65wjeKzFCjxk3HWMFdkyLhmLiJpSa7xPd8ET1pueaQpuuTy-2BzO2g-3D-3Dv8ws_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXCFer42JBFsKuMJ5Dk1W6V6GuH6R548-2FNCtHhtbAl0f094W4H5DD1zm-2FJKRaeL0EJJZrM8sOWbKbenHjTbvrWLp00WoZTkoZX01OKyWSBRY7cxfzEN7UHEGOTHwG61C0MTkAK7Ffk8sFfN0rc-2FCOHsYlXIkJyGteWvsWDEMWnIBw-3D-3D) (Jun 25), a healthcare data analyst (pundit) estimated ACA enrollment losses of **4–5 million** this year as enhanced subsidies lapse, with internal federal data reportedly showing >3M dropped by April, and some states (North Carolina) down >20%. Layer on Medicaid work-reporting (live in Nebraska; Arkansas/Montana July 1) and you get a shrinking, adverse-selecting risk pool, a "half death spiral."
- **Hospitals (HCA, THC, UHS):** Two-sided. 340B, **16% of all U.S. drug sales**, per [Telltales](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOiwdha9KrNM-2BcQNce4As52hFYHdr4PuSydMFC9S1PBz9aDbyZwqkqvjH6-2FZOsHLNKAEEKBwnoGGrk-2BbrdgLHtNfw4pnks4FssSvNxGUgW5JXg-3D-3DPpvA_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXCFer42JBFsKuMJ5Dk1W6V6GuH6R548-2FNCtHhtbAl0fwvgyiC5He2QeeX0JEP0jWUfwYXKwXa5QAfoXWdJiQ4e3Zm-2FJqhnz2VE5tO4vZNnDaMTQTikfosPk4FFywfYQ7DREgaM7ySIYQv1dwC5qTgTeujg8-2BjTDS-2FRiGLyBT04fg-3D-3D) (Jul 1, investor panel, pundit), is under attack: Lilly is demanding proof-of-need before paying rebates, and Sen. Cassidy introduced legislation this week to standardize (and arguably tighten) hospital data requirements. Meanwhile coverage losses threaten rural facilities.
- **PBMs / Optum-style services:** Kleinrock's most underappreciated point, IRA "price negotiation... lowers the reimbursement price and may remove some of the rebates" that cross-subsidize premiums. Gross-to-net ($1.36T list vs $606B net) is where the value actually sits. Direct-to-consumer channels (TrumpRx, Cost Plus) are a slow disintermediation threat.
- **Biosimilars/generics & ex-US:** Biosimilar savings keep getting offset by migration to novel therapies (the Humira/Stelara pattern), and generic GLP-1s remain years off given biologic complexity, so the "savings cliff" the bulls keep waiting for isn't arriving on schedule.

## What changed this week

- Medicare GLP-1 **Bridge Program went live July 1**; the Medicare arm of **Balance was pulled** (Medicaid-only now, through 2027).
- **Sen. Cassidy introduced 340B legislation** standardizing manufacturer data demands, the first legislative response to Lilly's rebate hardball.
- Medicaid **work-reporting requirements** began phasing in (Nebraska live; Arkansas/Montana July 1).